Skip to content
LexBuild

Medical Devices; Reprocessed Single-Use Devices; Requirement for Submission of Validation Data; Withdrawal

---
identifier: "/us/fr/07-105"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Medical Devices; Reprocessed Single-Use Devices; Requirement for Submission of Validation Data; Withdrawal"
title_number: 0
title_name: "Federal Register"
section_number: "07-105"
section_name: "Medical Devices; Reprocessed Single-Use Devices; Requirement for Submission of Validation Data; Withdrawal"
positive_law: false
currency: "2007-01-12"
last_updated: "2007-01-12"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "07-105"
document_type: "rule"
publication_date: "2007-01-12"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
cfr_references:
  - "21 CFR Part 807"
  - "21 CFR Part 868"
  - "21 CFR Part 870"
  - "21 CFR Part 872"
  - "21 CFR Part 874"
  - "21 CFR Part 876"
  - "21 CFR Part 878"
  - "21 CFR Part 880"
  - "21 CFR Part 882"
  - "21 CFR Part 884"
  - "21 CFR Part 886"
  - "21 CFR Part 892"
fr_citation: "72 FR 1460"
fr_volume: 72
docket_ids:
  - "Docket No. 2006N-0335"
fr_action: "Direct final rule; withdrawal."
---

#  Medical Devices; Reprocessed Single-Use Devices; Requirement for Submission of Validation Data; Withdrawal

**ACTION:**

Direct final rule; withdrawal.

**SUMMARY:**

The Food and Drug Administration (FDA) published a direct final rule that appeared in the *Federal Register* of September 25, 2006 (71 FR 55729), that would have amended certain classification regulations for reprocessed single-use devices (SUDs) whose exemption from premarket notification (510(k)) requirements have been terminated and other reprocessed SUDs already subject to premarket notification for which validation data, as specified under the Medical Device User Fee and Modernization Act of 2002, are necessary in a 510(k). FDA stated in the direct final rule that, if it received a significant adverse comment by December 11, 2006, FDA would publish a notice of withdrawal. FDA received two comments and considers at least one of these comments a significant adverse comment and, therefore, is withdrawing the direct final rule. Accordingly, the agency will consider the comments received under our usual procedures for notice and comment in connection with the notice of proposed rulemaking that was published in the *Federal Register* of September 25, 2006 (71 FR 55748) as a companion to the direct final rule.

**DATES:**

The direct final rule published at 71 FR 55729 on September 25, 2006, is withdrawn as of January 12, 2007.

**FOR FURTHER INFORMATION CONTACT:**

Heather S. Rosecrans, Center for Devices and Radiological Health (HFZ-404), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 240-276-4040.

Authority: Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, the direct final rule published on September 25, 2006 (71 FR 55729), is withdrawn.

Dated: January 9, 2007.

Jeffrey Shuren,

Assistant Commissioner for Policy.